Scher HI - Search Results

1

HER-2 profiling and targeting in prostate carcinoma.

Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. Morris MJ, et al. Among authors: scher hi. Cancer. 2002 Feb 15;94(4):980-6. Cancer. 2002. PMID: 11920466 Free article. Clinical Trial.

2

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Seidman AD, et al. Among authors: scher hi. J Urol. 1992 Mar;147(3 Pt 2):931-4. doi: 10.1016/s0022-5347(17)37426-8. J Urol. 1992. PMID: 1371564 Clinical Trial.

3

Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity.

Conti JA, Scher HI. Conti JA, et al. Among authors: scher hi. Cancer. 1992 Dec 1;70(11):2699-702. doi: 10.1002/1097-0142(19921201)70:11<2699::aid-cncr2820701122>3.0.co;2-c. Cancer. 1992. PMID: 1384952

4

Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy.

Zelefsky MJ, Scher HI, Krol G, Portenoy RK, Leibel SA, Fuks ZY. Zelefsky MJ, et al. Among authors: scher hi. Cancer. 1992 Nov 1;70(9):2319-25. doi: 10.1002/1097-0142(19921101)70:9<2319::aid-cncr2820700918>3.0.co;2-8. Cancer. 1992. PMID: 1394060

5

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Among authors: scher hi. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

6

Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy.

Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL. Petrylak DP, et al. Among authors: scher hi. Cancer. 1992 Dec 15;70(12):2870-8. doi: 10.1002/1097-0142(19921215)70:12<2870::aid-cncr2820701225>3.0.co;2-f. Cancer. 1992. PMID: 1451069

7

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.

Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ. Ilson DH, et al. Among authors: scher hi. J Clin Oncol. 1992 Jul;10(7):1124-30. doi: 10.1200/JCO.1992.10.7.1124. J Clin Oncol. 1992. PMID: 1607918 Clinical Trial.

8

Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors.

Motzer RJ, Cooper K, Geller NL, Pfister DG, Lin SY, Bajorin D, Scher HI, Herr H, Fair W, Morse M, et al. Motzer RJ, et al. Among authors: scher hi. Cancer. 1990 Jun 1;65(11):2465-70. doi: 10.1002/1097-0142(19900601)65:11<2465::aid-cncr2820651112>3.0.co;2-7. Cancer. 1990. PMID: 1692505

9

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.

Scher HI, Curley T, Geller N, Engstrom C, Dershaw DD, Lin SY, Fitzpatrick K, Nisselbaum J, Schwartz M, Bezirdjian L, et al. Scher HI, et al. J Clin Oncol. 1990 Nov;8(11):1830-8. doi: 10.1200/JCO.1990.8.11.1830. J Clin Oncol. 1990. PMID: 1700078

10

Use of adaptive control with feedback to individualize suramin dosing.

Scher HI, Jodrell DI, Iversen JM, Curley T, Tong W, Egorin MJ, Forrest A. Scher HI, et al. Cancer Res. 1992 Jan 1;52(1):64-70. Cancer Res. 1992. PMID: 1727387

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

698 results

Search Page

Filters